Table 5.
Determinants of receiving anticoagulants in the 6 months after the diagnosis of atrial fibrillation (binary logistic regression analysis, n = 1830)
| Bivariate | P value | Multivariable | P value | |
|---|---|---|---|---|
| OR (95 % CI) | OR 95 % CI | |||
| Age (years)a | 0.98 (0.96–0.99) | <0.001 | 1.00 (0.98–1.01) | 0.74 |
| Men | 1.3 (1.1–1.6) | 0.002 | 1.5 (1.2–1.8) | 0.001 |
| Medicationa | ||||
| Digitalis | 1.9 (1.4–2.5) | <0.001 | 2.0 (1.4–2.7) | <0.001 |
| Antiarrhythmic drug | 2.4 (1.9–3.0) | <0.001 | 2.0 (1.6–2.5) | <0.001 |
| Antihypertensive medication | ||||
| Diuretic | 2.5 (2.1–3.0) | <0.001 | 1.5 (1.2–1.9) | 0.001 |
| β blocker | 3.1 (2.5–3.7) | <0.001 | 2.4 (1.9–2.9) | <0.001 |
| Calcium channel blocker | 2.2 (1.7–2.8) | <0.001 | 1.6 (1.2–2.1) | 0.003 |
| ACE-inhibitor | 2.1 (1.7–2.6) | <0.001 | 1.5 (1.1–1.9) | 0.003 |
| ARB | 3.0 (2.2–4.3) | <0.001 | 2.3 (1.6–3.4) | <0.001 |
| Comorbiditya | ||||
| CHADS2 scoreb | 1.0 (0.94–1.1) | 0.64 | 1.1 (0.99–1.3)c | 0.079 |
| CHA2DS2-VASc scoreb | 0.98 (0.92–1.0) | 0.57 | 1.1 (0.99–1.3)d | 0.086 |
| Charlson Comorbidity Indexb | 0.91 (0.86–0.96) | <0.001 | 0.90 (0.83–0.97)c | 0.009 |
| Myocardial infarction | 1.0 (0.79–1.4) | 0.77 | 0.84 (0.61–1.2) | 0.29 |
| Heart failure | 0.99 (0.74–1.3) | 0.92 | 1.0 (0.72–1.4) | 0.92 |
| Peripheral vascular disease | 1.2 (0.86–1.7) | 0.30 | 1.2 (0.80–1.7) | 0.41 |
| Cerebrovascular event | 1.1 (0.82–1.4) | 0.66 | 1.2 (0.86–1.6) | 0.32 |
| Dementia | 0.19 (0.097–0.38) | <0.001 | 0.26 (0.12–0.56) | <0.001 |
| Chronic pulmonary disease | 1.9 (1.0–3.4) | 0.041 | 1.9 (0.97–3.7) | 0.062 |
| History of peptic ulcers | 0.74 (0.53–1.0) | 0.078 | 0.66 (0.45–0.96) | 0.031 |
| Liver disease | 0.94 (0.55–1.6) | 0.81 | 0.94 (0.51–1.7) | 0.85 |
| Diabetes | 1.2 (0.96–1.6) | 0.11 | 1.1 (0.85–1.5) | 0.40 |
| Hemiplegia | 0.60 (0.28–1.3) | 0.18 | 0.77 (0.33–1.8) | 0.56 |
| Renal disease | 0.84 (0.73–0.97) | 0.021 | 0.88 (0.74–1.0) | 0.14 |
| History of tumours | 0.70 (0.53–0.93) | 0.013 | 0.67 (0.49–0.92) | 0.012 |
| Leukaemia | 0.26 (0.029–2.3) | 0.23 | 0.36 (0.038–3.5) | 0.38 |
| Lymphoma | 1.4 (0.31–6.2) | 0.66 | 0.93 (0.19–4.5) | 0.92 |
| Hypertension | 1.3 (1.0–1.5) | 0.016 | 1.0 (0.82–1.3) | 0.86 |
| Valve disease | 1.2 (0.88–1.6) | 0.24 | 1.2 (0.87–1.8) | 0.24 |
| Cerebrovascular event in the first 6 months after diagnosis of atrial fibrillation | 1.6 (1.0–2.6) | 0.042 | 1.8 (1.0–3.1) | 0.039 |
a All variables were recorded at baseline (= date of the diagnosis of atrial fibrillation for the case), except cerebrovascular event in the first 6 months after the diagnosis of atrial fibrillation; b, per point increase; c, adjusted for age, gender, digitalis intake, antiarrhythmic drug intake, diuretic intake, β blocker intake, calcium channel blocker intake, ACE inhibitor intake, ARB intake, valve disease, cerebrovascular event in the first 6 months after diagnosis of atrial fibrillation and CHADS2 or Charlson Comorbidity index; d, adjusted for age, digitalis intake, antiarrhythmic drug intake, diuretic intake, β blocker intake, calcium channel blocker intake, ACE inhibitor intake, ARB intake, valve disease, cerebrovascular event in the first 6 months after diagnosis of atrial fibrillation and Charlson Comorbidity index (the correlation coefficient between the CHADS2 and the CHA2DS2-VASc score was 0.91)
OR odds ratio, CI confidence interval, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker